17.07.2024 / Innovative approaches for vaccine trials as a key component of pandemic preparedness – a white paper (Infection): https://link.springer.com/article/10.1007/s15010-024-02347-1
09.07.2024 / Immunogenicity, reactogenicity and safety of a second booster with BNT162b2 or full-dose mRNA-1273: a randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1-AGED Part B) (Int J Infect Dis.): https://pubmed.ncbi.nlm.nih.gov/38992789/
28.05.2024 / Challenges in assessing the immunization status of adults in Germany—lessons from a population-based VACCELERATE survey on polio vaccination (Infection): https://link.springer.com/article/10.1007/s15010-024-02296-9
25.04.2024 / Coordination of COVID‑19 platform trials in Europe (Trials): https://link.springer.com/epdf/10.1186/s13063-024-08126-5?sharing_token=CVTdqgfhPgvP3eLWTbZq_m_BpE1tBhCbnbw3BuzI2RPA43QxTXTJzEKHg7F__ALEJb0D29J3qOSXX11reLVyoVEgyjF9YzsQPg9zPzE6Cq8Cqzm96oLjtmusdk6eCtROp76kHWqAt0Tuc9nYxbZ6cVmAHXbw4pbpbsoTzZeqF0k%3D
04.04.2024 / Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study (JMIR): https://publichealth.jmir.org/2024/1/e47241
22.12.2023 / Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B) (Preprints with The Lancet): https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4671824
06.12.2023 / Predicting the next pandemic: VACCELERATE ranking of the World health Organization's Blueprint for action to prevent epidemics (Travel Medicine and Infectious Disease): https://www.sciencedirect.com/science/article/pii/S1477893923001369
29.11.2923 / The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium (vaccines): https://www.mdpi.com/2076-393X/11/12/1784/htm
02.11.2023 / Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time (nature communications): https://www.nature.com/articles/s41467-023-42717-1.pdf
31.10.2023 / Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1) (Vaccine): https://www.sciencedirect.com/science/article/pii/S0264410X23012136
27.10.2023 / Epidemiology of Acute Respiratory Infection with SARS-CoV-2, Influenza A & B Viruses, Respiratory Syncytial Virus, and Adenovirus in VACCELERATE Volunteers in Germany (Preprints with THE LANCET): https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4612721
01.09.2023 / Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis (Cochrane Library): https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000065.pub2/full
18.05.2023 / VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe (Vaccine): https://www.sciencedirect.com/science/article/pii/S0264410X23005236
03.04.2023 / Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit (JMIR Publications): https://publichealth.jmir.org/2023/1/e44491
07.12.2022 / Efficacy and safety of COVID‐19 vaccines (Cochrane Library): https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015477/epdf/full
11.2022 / Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination (Journal of Immunological Methods): https://www.sciencedirect.com/science/article/pii/S0022175922001326
10.2022 / Monkeypox diagnostic and treatment capacity at epidemic onset: A VACCELERATE online survey (Journal of Infection and Public Health): https://www.sciencedirect.com/science/article/pii/S1876034122002118?via%3Dihub
08.10.2022 / A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network (Trials): https://pubmed.ncbi.nlm.nih.gov/36209129/
04.10.2022 / Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 (eBioMedicine): https://pubmed.ncbi.nlm.nih.gov/36206622/
19.09.2022 / Monkeypox in children and adult women in Europe: Results from a flash VACCELERATE pilot survey (Enfermedades Infecciosas y Microbiología Clínica): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534071/
31.08.2022 / Vaccination rates in Europe are not associated with online media intensity (JCOM Journal of Science Communication): https://jcom.sissa.it/archive/21/05/JCOM_2105_2022_A05
18.06.2022 / A pilot surveillance report of SARS-CoV-2 rapid antigen test results among volunteers in Germany, 1st week of July 2022 (Infection): https://link.springer.com/article/10.1007/s15010-022-01931-7
13.06.2022 / Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR (Nature Biotechnology): https://www.nature.com/articles/s41587-022-01347-6
02.06.2022 / VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment (Vaccine): https://www.sciencedirect.com/science/article/pii/S0264410X22006053?via%3Dihub
05.04.2022 / A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern (Communications Medicine): https://www.nature.com/articles/s43856-022-00091-x
23.03.2022 / Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination (Frontiers in Immunology): https://www.frontiersin.org/articles/10.3389/fimmu.2022.845882/full
11.01.2022 / Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis (Cochrane Library): https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000065/full
04.10.2021 / Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days (Frontiers in Immunology): https://www.frontiersin.org/articles/10.3389/fimmu.2021.726960/full
03.08.2021 / Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals (Cell Reports): https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01004-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124721010044%3Fshowall%3Dtrue
29.07.2021 / Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 (The Lancet Infectious Diseases): https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00420-5/fulltext
27.05.2021 / Reactogenicity and Immunogenicity of BNT162b2 in Subjects Having Received a First Dose of ChAdOx1s: Initial Results of a Randomised, Adaptive, Phase 2 Trial (CombiVacS) (The Lancet): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233007/